<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949948</url>
  </required_header>
  <id_info>
    <org_study_id>REK 2011/2435</org_study_id>
    <nct_id>NCT01949948</nct_id>
  </id_info>
  <brief_title>Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke</brief_title>
  <acronym>NOR-TEST</acronym>
  <official_title>Randomised Trial of Tenecteplase vs. Alteplase for Recanalisation in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Thomassen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Alteplase dissolves blood vessel clots in acute ischemic stroke and is the only
      approved acute drug treatment &lt;4½ hours of stroke onset. The overall benefit from alteplase
      is substantial, but up to 2/3 of patients with large artery clots may not achieve reopening
      of the vessel and up to 40% of the patients may remain severely disabled or die, leaving
      substantial room for improvement. Tenecteplase, widely used in coronary heart disease, may be
      more effective and may have less bleeding complications than alteplase, and may be the drug
      of choice also in stroke.

      HYPOTHESIS: Tenecteplase may be given safely to patients with acute ischemic stroke at a dose
      that is associated with improved clinical outcome compared with existing treatment options.

      AIMS: To compare efficacy and safety of tenecteplase vs. alteplase given &lt;4½ hours after
      symptom onset.

      STUDY ENDPOINTS: The primary study endpoint is excellent clinical outcome at 3 months
      (effect). Secondary study endpoints are major early clinical improvement (effect) and
      bleeding complications (safety).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HYPOTHESIS: 1) Tenecteplase 0.4 mg/kg may be given safely to patients with acute ischaemic
      stroke &lt;4½ hours after stroke onset. 2) Tenecteplase 0,4 mg/kg (single bolus)has superior
      efficacy and safety compared with alteplase 0.9 mg/kg (10% bolus + 90% infusion/60 minutes)
      when given within 4 ½ hours after stroke onset.

      DESIGN: NOR-TEST is a multi-centre PROBE (prospective randomised, open-label, blinded
      endpoint) trial with randomisation tenecteplase:alteplase 1:1.

      POWER CALCULATION: NOR-TEST aims at detecting a 9 % higher percentage excellent outcome with
      tenecteplase vs. alteplase (r1=0.40; r2=0.49; OR 1.44; power 0.8), and will include 954
      patients during 3 years.

      PATIENT RECRUITMENT: All patients found eligible for thrombolytic therapy are eligible for
      NOR-TEST, i.e. NOR-TEST changes neither inclusion nor exclusion criteria. The number of
      patients treated at a participating centre will therefore essentially remain unchanged.
      Estimated 400 patients are thrombolysed per year in participating centres. Allowing for 20%
      of patients not being included in NOR-TEST, the total number of patients (n=954) will still
      be met.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2012</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical: Functional handicap</measure>
    <time_frame>90 days</time_frame>
    <description>Excellent outcome defined as mRS 0-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic cerebral hemorrhage</measure>
    <time_frame>24-36 hours</time_frame>
    <description>Haemorrhagic transformation (haemorrhagic infarct / haematoma) as defined by CT (or MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic transformation</measure>
    <time_frame>24-36 hours</time_frame>
    <description>Any hemorrhagic infarct or parenchymal hematoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological improvement</measure>
    <time_frame>24 hours</time_frame>
    <description>NIHSS changes from baseline: NIHSS=0 or reduction of ≥4 NIHSS points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Functional handicap</measure>
    <time_frame>90 days</time_frame>
    <description>Ordinal shift analysis of mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>90 days</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1050</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Tenecteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.4 mg/kg single bolus intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>0.4 mg/kg single bolus intravenously</description>
    <arm_group_label>Tenecteplase</arm_group_label>
    <other_name>Metalyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously</description>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>Actilyse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Ischaemic stroke with measurable deficit on NIH Stroke Scale

          -  All stroke sub-types, severities and vascular distributions,a visible arterial
             occlusion is not required for inclusion

          -  Treatment within 4 ½ hours of stroke onset

          -  Patients awakening with symptoms are defined by the time last observed normal and
             awake

          -  Informed written consent signed by the patient, verbal consent from the patients as
             witnessed by a non-participating health care person, or consent by the signature of
             the patient's family must be provided

        Exclusion Criteria:

          -  Patients with premorbid modified Rankin Scale (mRS) score ≥3

          -  Patients for whom a complete NIH Stroke Score cannot be obtained

          -  Hemiplegic migraine with no arterial occlusion on CTA

          -  Seizure at stroke onset and no visible occlusion on baseline CTA

          -  Intracranial haemorrhage on baseline CT

          -  Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is
             normal

          -  Large areas of hypodense ischaemic changes on baseline CT

          -  Patients with systolic blood pressure &gt;185 mm Hg or diastolic blood pressure &gt;110 mm
             Hg

          -  Female, pregnant or breast feeding

          -  Known bleeding diathesis

          -  Use of oral anticoagulants and International Normalized Ratio (INR) ≥1,4

          -  Use of new oral anticoagulants (NOAC) within the last 12 hours

          -  Heparin &lt;48 hours and increased Activated partial thromboplastin tike (APTT)

          -  Low molecular weight heparin(oid) &lt;24 hours

          -  Any other investigational drug &lt;14 days

          -  Sepsis

          -  Patients with arterial puncture at a noncompressible site or lumbar puncture &lt;7 days

          -  Major surgery or serious trauma &lt;14 days

          -  Gastrointestinal or urinary tract hemorrhage &lt;14 days

          -  Clinical stroke &lt;2 months

          -  History of intracranial haemorrhage

          -  Brain neurosurgery &lt;2 months

          -  Serious head trauma &lt;2 months

          -  Pericarditis

          -  Any serious medical illness likely to interact with treatment

          -  Confounding pre-existent neurological or psychiatric disease

          -  Unlikely to complete follow-up

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Thomassen, MD PhD Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. Neurology, Haukeland University HospitalBergen, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Waje-Andreassen, MD PhD Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Dept. Neurology, Haukeland University Hospital, Bergen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Logallo, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Neurology, Haukeland University Hospital, Bergen, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordland Hospital</name>
      <address>
        <city>Bodø</city>
        <zip>8092</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Førde Central Hospital</name>
      <address>
        <city>Førde</city>
        <zip>6800</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haugesund Hospital</name>
      <address>
        <city>Haugesund</city>
        <zip>5516</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molde Hospital</name>
      <address>
        <city>Molde</city>
        <zip>6400</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Nordbyhagen</city>
        <zip>1474</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullevål University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baerum Hospital</name>
      <address>
        <city>Rud</city>
        <zip>1309</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Telemark Hospital</name>
      <address>
        <city>Skien</city>
        <zip>3710</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hosital</name>
      <address>
        <city>Stavanger</city>
        <zip>4017</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olav Hospital NTNU</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tønsberg Hospital</name>
      <address>
        <city>Tønsberg</city>
        <zip>3100</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Logallo N, Kvistad CE, Nacu A, Naess H, Waje-Andreassen U, Asmuss J, Aamodt AH, Lund C, Kurz MW, Rønning OM, Salvesen R, Idicula TT, Thomassen L. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol. 2014 May 15;14:106. doi: 10.1186/1471-2377-14-106.</citation>
    <PMID>24886064</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2013</study_first_submitted>
  <study_first_submitted_qc>September 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Haukeland University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Thomassen</investigator_full_name>
    <investigator_title>Senior Consultant neurologist; Professor</investigator_title>
  </responsible_party>
  <keyword>treatment, intervention, thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

